The outlook for life sciences IPOs is showing renewed optimism heading into 2025, with market conditions becoming more constructive and regulatory environments potentially more favorable....more
As biotech markets begin to show signs of life, how should company leaders and investors prepare for what’s next?
Biotech executives, investment bankers and partners from Deloitte’s life sciences practice and Fenwick’s...more